Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: Immediate clinical and hemodynamic outcome and one-year follow-up

Journal of the American College of Cardiology

Volumn 31, Issue 5, 1998, Pages 1057-1063

  Meneveau, Nicolas ^a   Schiele, François ^a   Metz, Damien ^b   Valette, Benoît ^c   Attali, Pierre ^d   Vuillemenot, Alain ^a   Grollier, Gilles ^c   Elaerts, Jacques ^b   Mossard, Jean Marie ^d   Viel, Jean François ^a   Bassand, Jean Pierre ^a  

^a HÔPITAL SAINT JACQUES   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c CHU CÔTE DE NACRE   (France)

^d Hopital Central Strasbourg   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; HEPARIN; STREPTOKINASE;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEMODYNAMICS; HEPARINIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; SINGLE-BLIND METHOD; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0032054707     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00068-0     Document Type: Article

References (33)

1. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 1973;47 Suppl II:II-1-108.
2. Urokinase-Streptokinase Pulmonary Embolism Trial, Phase 2 results: a cooperative study. JAMA 1974;229:1606-13.
3. Dalla-Volta S, Palla A, Santolicandro A, et al. Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: plasminogen Activator Italian Multicenter Study 2 (PAIMS 2). J Am Coll Cardiol 1992;20:520-6.
4. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-11.
5. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997;96:882-8.
6. Goldhaber SZ, Heit J, Sharma GVRK, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293-8.
7. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol 1992;19:239-45.
8. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992;20:24-30.
9. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolism: an international multicenter randomized trial. Chest 1994;106:718-23.
10. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simmoneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest 1994;106:712-7.
11. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase versus alteplase in massive pulmonary embolism: a randomized trial assessing right heart hemodynamics and pulmonary vascular obstruction. Eur Heart J 1997;18: 1141-8.
12. Jerjes-Sanchez C, Ramirez-Rivera A, Garcia-Molinedo M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombol 1995;2:67-9.
13. Third International Study of Infarct Survival Collaborative Group. ISIS 3: a randomised comparison of Streptokinase vs tissue plasminogen activator vs anistreplase and aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
14. The Gusto Angiographic Investigators. The effects of tissue plasminogen activator, SK, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
15. Miller GAH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of Streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. BMJ 1971;2:681-4.
16. Meyer G, Collignon MA, Guinet F, Jeffrey AA, Barritault L, Sors H. Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med 1990; 17:315-9.
17. Petitprez P, Simmoneau G, Cerrina J, et al. Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. Circulation 1984;70:861-6.
18. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in the treatment of life-threatening pulmonary embolism. BMJ 1974;1:343-47.
19. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978;203:465-70.
20. Luomanmaki K, Halttunen PK, Hekali P, Valle M, Heikkila J. Experience with streptokinase treatment of major pulmonary embolism. Ann Clin Res 1983;15:21-5.
21. Uzbek C, Sen S, Frank S, Dyckmans J, Schiffer H. Rapid high dose streptokinase in severe pulmonary embolism. Lancet 1989;2:229-30.
22. Diehl JL, Meyer G, Igual J, et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992;70:1477-80.
23. Meneveau N, Bassand JP, Schiele F, et al. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients. J Am Coll Cardiol 1993;22:1075-9.
24. Lew AS, Laramee P, Cercek B, Shah PK, Ganz W. The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation 1985;72:1321-6.
25. Hall RJC, Sutton GC, Kerr IH. Long-term prognosis of treated acute massive pulmonary embolism. Br Heart J 1977;39:1128-34.
26. Lund O, Nielsen TT, Ronne K, Schiffer S. Pulmonary embolism: long term follow-up after treatment with full-dose heparin, streptokinase or embolectomy. Acta Med Scand 1987;221:61-71.
27. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980;303:842-5.
28. Meyer G, Stern M, Charbonnier B, Brochier ML. Thrombolysis in acute pulmonary embolism. In: Julian D, Kübier W, Norris RM, Swan HJC, Collen D, Verstraete M, editors. Thrombolysis in Cardiovascular Disease. New York: Marcel Dekker, 1989:337-60.
29. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992;326:1240-5.
30. Benotti JR, Ockene IS, Alpert JS, Dalen JE. The clinical profile of unresolved pulmonary embolism. Chest 1983;84:669-78.
31. Rich S, Levitsky S, Brundage BH. Pulmonary hypertension from chronic pulmonary thromboembolism. Ann Intern Med 1988;108:425-34.
32. Paraskos JA, Adelstein SJ, Smith RE, et al. Late prognosis of acute pulmonary embolism. N Engl J Med 1973;289:55-8.
33. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990;81:1735-43.